<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article199</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/VASST" style="display:block; margin-bottom:10px;">VASST Original</a></li>
<h2><strong>VASST</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Vasopressin vs Norepinephrine in Septic Shock". The New England Journal of Medicine. Date unknown. Volume and issue unknown: Page numbers unknown. PubMed link•Full text•PDF<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does low-dose vasopressin reduce mortality among patients with septic shock who are being treated with catecholamine vasopressors compared to norepinephrine?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Low-dose vasopressin did not reduce mortality rates as compared with norepinephrine among patients with septic shock who were treated with catecholamine vasopressors.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Modern guidelines from the ACC/AHA do not comment on the use of antiarrhythmic medications in ACS care.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, randomized, double-blind trial.<br/>
- N=778 patients with septic shock on a minimum of 5 μg of norepinephrine per minute.<br/>
- Intervention: Low-dose vasopressin (0.01 to 0.03 U per minute) (n=396) vs norepinephrine (5 to 15 μg per minute) (n=382).<br/>
- All vasopressor infusions were titrated and tapered to maintain a target blood pressure.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Patients age 16 and older with septic shock and low-dose norepinephrine.<br/>
- Excluded if septic shock was unresponsive to fluids or if specific exclusion criteria were met. <br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Patients received either low-dose vasopressin or norepinephrine infusion in addition to open-label vasopressors, titrated to maintain target blood pressure.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary: 28-day mortality rate.<br/>
- Secondary: 90-day mortality, days free of organ dysfunction, vasopressor use, ventilation, SIRS, corticosteroid use, and length of ICU and hospital stay.<br/>
- Serious adverse events.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Infusion range of vasopressin was fixed, and no adjustments were made based on vasopressin levels.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Canadian Institutes of Health Research.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Original study: The New England Journal of Medicine (Link provided in the full article).
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
